Back to results
US 2023/0142522 A1Published application
Anti-tcr antibody molecules and uses thereof
AssigneeMarengo Therapeutics, Inc.
InventorsSeng-Lai Tan, Brian Edward Vash, Jonathan Hsu, Dilini Charmain Gunasekera, Sangeetha Sagar Palakurthi, Andreas Loew
Life of this patent
Estimating the term…
Abstract
The disclosure provides antibody molecules that bind to TCR Vβ regions and multispecific molecules comprising said antibody molecules. Additionally, disclosed are nucleic acids encoding the same, methods of producing the aforesaid molecules, pharmaceutical compositions comprising aforesaid molecules, and methods of treating a cancer using the aforesaid molecules.
Claims30
A method of clonal expansion of T cells that express a T cell receptor beta variable region (TCRβV) in a T cell population, the method comprising:
- contacting the T cell population with a composition comprising a multispecific molecule,
- wherein the multispecific molecule comprises a first domain that binds to a first target molecule and a second domain that binds to a second target molecule,
- wherein the first target molecule is a TCRβV,
- wherein the multispecific molecule is a TCRβV agonist,
- wherein the second domain comprises a tumor-targeting domain, a cytokine molecule, or a stromal modifying domain, and
- wherein the first domain contacts the TCRβV of a T cell receptor (TCR) expressed by the T cells in the T cell population, thereby clonally expanding memory T cells in the T cell population that express the TCR comprising the TCRβV at least about 2-fold.
3 more elements
Dependencies are inferred from the claim text.